A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer

Gynecologic Oncology

Volumn 114, Issue 3, 2009, Pages 457-464

  Hu, Xiaoxia ^a   Macdonald, Dusten M ^a   Huettner, Phyllis C ^a   Feng, Zhihui ^a   El Naqa, Issam M ^a   Schwarz, Julie K ^a   Mutch, David G ^a   Grigsby, Perry W ^a   Powell, Simon N ^a   Wang, Xiaowei ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Expression profiling; microRNA; Ovarian cancer; Prognosis; Real time PCR

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA MIR 200A; MICRORNA MIR 200B; MICRORNA MIR 429; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

ADULT; ADVANCED CANCER; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CELL CULTURE; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM CANCER; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH;

CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; HUMANS; MICRORNAS; MIDDLE AGED; MULTIGENE FAMILY; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 67651165020     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.05.022     Document Type: Article

References (33)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J. Clin. 58 2 (2008) 71-96
2. Bast Jr. R.C., and Hortobagyi G.N. Individualized care for patients with cancer - a work in progress. N. Engl. J. Med. 351 27 (2004) 2865-2867
3. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351 27 (2004) 2817-2826
4. Spentzos D., Levine D.A., Ramoni M.F., Joseph M., Gu X., Boyd J., et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J. Clin. Oncol. 22 23 (2004) 4700-4710
5. Berchuck A., Iversen E.S., Lancaster J.M., Pittman J., Luo J., Lee P., et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin. Cancer Res. 11 10 (2005) 3686-3696
6. Bonome T., Levine D.A., Shih J., Randonovich M., Pise-Masison C.A., Bogomolniy F., et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 68 13 (2008) 5478-5486
7. Ambros V. The functions of animal microRNAs. Nature 431 7006 (2004) 350-355
8. Miska E.A. How microRNAs control cell division, differentiation and death. Curr. Opin. Genet. Dev. 15 5 (2005) 563-568
9. Jay C., Nemunaitis J., Chen P., Fulgham P., and Tong A.W. miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol. 26 5 (2007) 293-300
10. Yang H., Kong W., He L., Zhao J.J., O'Donnell J.D., Wang J., et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 68 2 (2008) 425-433
11. Iorio M.V., Visone R., Di Leva G., Donati V., Petrocca F., Casalini P., et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 67 18 (2007) 8699-8707
12. Yang N., Kaur S., Volinia S., Greshock J., Lassus H., Hasegawa K., et al. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res. 68 24 (2008) 10307-10314
13. Dahiya N., Sherman-Baust C.A., Wang T.L., Davidson B., Shih Ie M., Zhang Y., et al. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS ONE 3 6 (2008) e2436
14. Nam E.J., Yoon H., Kim S.W., Kim H., Kim Y.T., Kim J.H., et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin. Cancer Res. 14 9 (2008) 2690-2695
15. Wang X. A PCR-based platform for microRNA expression profiling studies. RNA 15 4 (2009) 716-723
16. Wang X., and Seed B. A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res. 31 24 (2003) e154
17. Reiner A., Yekutieli D., and Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 19 3 (2003) 368-375
18. Wang X., and El Naqa I.M. Prediction of both conserved and nonconserved microRNA targets in animals. Bioinformatics 24 3 (2008) 325-332
19. Wang X. miRDB: a microRNA target prediction and functional annotation database with a wiki interface. RNA 14 6 (2008) 1012-1017
20. Park S.M., Gaur A.B., Lengyel E., and Peter M.E. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 22 7 (2008) 894-907
21. Korpal M., Lee E.S., Hu G., and Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 283 22 (2008) 14910-14914
22. Gregory P.A., Bert A.G., Paterson E.L., Barry S.C., Tsykin A., Farshid G., et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 10 5 (2008) 593-601
23. Rybak J.N., Roesli C., Kaspar M., Villa A., and Neri D. The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Res. 67 22 (2007) 10948-10957
24. Kenny H.A., Kaur S., Coussens L.M., and Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J. Clin. Invest. 118 4 (2008) 1367-1379
25. Koh C.G., Tan E.J., Manser E., and Lim L. The p21-activated kinase PAK is negatively regulated by POPX1 and POPX2, a pair of serine/threonine phosphatases of the PP2C family. Curr. Biol. 12 4 (2002) 317-321
26. Lipschutz J.H., Guo W., O'Brien L.E., Nguyen Y.H., Novick P., and Mostov K.E. Exocyst is involved in cystogenesis and tubulogenesis and acts by modulating synthesis and delivery of basolateral plasma membrane and secretory proteins. Mol. Biol Cell. 11 12 (2000) 4259-4275
27. Petit M.M., Schoenmakers E.F., Huysmans C., Geurts J.M., Mandahl N., and Van de Ven W.J. LHFP, a novel translocation partner gene of HMGIC in a lipoma, is a member of a new family of LHFP-like genes. Genomics 57 3 (1999) 438-441
28. Kvissel A.K., Ramberg H., Eide T., Svindland A., Skalhegg B.S., and Tasken K.A. Androgen dependent regulation of protein kinase A subunits in prostate cancer cells. Cell Signal 19 2 (2007) 401-409
29. Imhof A., Schuierer M., Werner O., Moser M., Roth C., Bauer R., et al. Transcriptional regulation of the AP-2alpha promoter by BTEB-1 and AP-2rep, a novel wt-1/egr-related zinc finger repressor. Mol. Cell Biol. 19 1 (1999) 194-204
30. Thaker P.H., Deavers M., Celestino J., Thornton A., Fletcher M.S., Landen C.N., et al. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin. Cancer Res. 10 15 (2004) 5145-5150
31. Meade-Tollin L., and Martinez J.D. Loss of p53 and overexpression of EphA2 predict poor prognosis for ovarian cancer patients. Cancer Biol. Ther. 6 2 (2007) 288-289
32. Lu C., Shahzad M.M., Wang H., Landen C.N., Kim S.W., Allen J., et al. EphA2 overexpression promotes ovarian cancer growth. Cancer Biol. Ther. 7 7 (2008)
33. Lin Y.G., Han L.Y., Kamat A.A., Merritt W.M., Landen C.N., Deavers M.T., et al. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer 109 2 (2007) 332-340